Locus Biosciences, Inc.

Locus is a clinical-stage biotechnology company developing precision medicines for therapeutic indications across infectious disease and inflammatory diseases. Once revolutionary, antibiotics are interfering with the effectiveness of novel, life-saving therapies and causing disease by disrupting the microbiome. The need to address infections with stronger antibiotics also has physicians weighing antibiotic toxicities in patients. Our vision is to revolutionize the treatment of disease and our crPhage™ and ePhage platforms decrease the burden of medicines on that patient to treat their disease. We completed a first-of-its-kind controlled clinical trial in January 2021, with a crPhage product targeting Escherichia coli bacteria causing urinary tract infections. We are continuing to advance our company into Phase 2 human efficacy trials with the support of our incredible partners.